Abattis Bioceuticals Corp.

Ordinary Shares International Reporting
Verified Company Profile 3/09/2017
Contact Info
  • Suite 104
  • 9295 198th Street
  • Langely, BC V1M3J9
  • Canada

Business Description

Financial Reporting/Disclosure
Reporting Status International Reporting: Canadian Securities Exchange
Audited Financials Audited
Latest Report Mar 31, 2017 Quarterly Report
CIK 0001515768
Fiscal Year End 9/30
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 2833 - Medicinal and botanicals
Incorporated In: British Columbia, Canada
Year of Inc. 1997
Employees Not Available
Company Officers/Contacts
Rene David CFO, COO
Michael Bluestein Securities Counsel
Company Directors
Guy Dancosse Independent Director, Audit Committee Member
James Irving Independent Director, Audit Committee Member
William Panenka Independent Director
Douglas Sorocco Independent Director, Audit Committee Member
Shuang Xie
Service Providers
Accounting/Auditing Firm
Dale Matheson Carr-Hilton Labonte LLP
1140 West Pender St.
Suite 1500 and 1700
Vancouver, BC, V6E 4G1
Securities Counsel Investor Relations Firm
Company History
  • Formerly=Abattis Biologix Corp. until 9-2012
ATTBF Security Details
Share Structure
Market Value1 $15,665,785 a/o Jun 28, 2017
Authorized Shares Unlimited a/o Feb 05, 2017
Outstanding Shares 133,895,599 a/o Feb 05, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 91,134,125 a/o Sep 06, 2016
Par Value Not Available
Shareholders of Record 199 a/o Sep 06, 2016
Non US Stock Exchange Listing
ATT - Canadian Securities Exchange - Qualified
Short Selling Data
Short Interest 5,955 (-77.99%)
Jun 15, 2017
Significant Failures to Deliver No

1Market Value calculated only for respective security